PSP Research’s Travere Therapeutics TVTX Stock Holding History

PSP Research’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,272	Closed	-$584K	–	99
2025 Q4	$584K	Buy	+15,272	New	+$497K	0.51%	3

Other funds holding TVTX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PSP Research's TVTX Position: Q1 2026 in Review

PSP Research sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 15,272 shares — an estimated $584K sold.

PSP Research first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $584K in Q4 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

PSP Research reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
PSP Research sold 15,272 Travere Therapeutics shares in Q1 2026, an estimated $584K.
PSP Research first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
PSP Research's Travere Therapeutics position peaked at $584K in Q4 2025.
261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.